Seaport Therapeutics initiates coverage with strong buy rating; price target $46
SPTX•Raymond James initiated coverage of Seaport Therapeutics with a strong buy rating and a $46 price target.
Related News
US equity funds post first inflow in five weeks on renewed AI optimism
SPY•
Marqeta to host conference call on third-quarter 2026 results
MQ•
Mexico August seasonally adjusted jobless rate 2.7%
EWZ•
Explosives detector maker Astrotech's FY revenue declines, net loss widens
ASTC•
Bernstein upgrades 3M, cites stronger growth and valuation outlook
MMM•